Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0PLPNX
ADC Name
SGN-ALPV
Synonyms
SGN ALPV
   Click to Show/Hide
Organization
Seagen Inc.
Drug Status
Phase 1
Indication
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 1
Drug-to-Antibody Ratio
4
Antibody Name
Undisclosed
Antigen Name
Alkaline phosphatase, germ cell type (ALPG)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05229900
Phase 1
A phase 1 study of SGN-ALPV in advanced solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05229900  Clinical Status Phase 1
Clinical Description A phase 1 study of SGN-ALPV in advanced solid tumors.
References
Ref 1 A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.